METHOD FOR TREATING OR PREVENTING THROMBOSIS USING >;150 MG TO 300 MG B.I.D. OF DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED EFFICACY OVER CONVENTIONAL WARFARIN THERAPY
592613 Disclosed herein is the use of dabigatran etexilate, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention of stroke in patients suffering from atrial fibrillation wherein the patient has no risk factors for major bleeding events, wherein the use comprises the administration 5 of a dosage of >;150 mg b.i.d. to 300 mg b.i.d. of dabigatran etexilate, or a pharmaceutically acceptable salt thereof.